A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Madani, Navid ^a,b   Princiotto, Amy M ^a   Mach, Linh ^b   Ding, Shilei ^c,d   Prevost, Jérémie ^c,d   Richard, Jonathan ^c,d   Hora, Bhavna ^e   Sutherland, Laura ^e   Zhao, Connie A ^a   Conn, Brandon P ^b   Bradley, Todd ^e   Moody, M Anthony ^e   Melillo, Bruno ^f   Finzi, Andrés ^c,d   Haynes, Barton F ^e   Smith, Amos B ^f   Santra, Sampa ^b   Sodroski, Joseph ^a,b,g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BNM III 170; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; N1 (4 CHLORO 3 FLUOROPHENYL) N2 [2 (GUANIDINOMETHYL) 5 ((METHYLAMINO)METHYL) 2,3 DIHYDRO 1H INDEN 1 YL]OXALAMIDE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODY; CELL COMPONENT; CHEMICAL COMPOUND; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNE SYSTEM; PROTEIN; VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; NONHUMAN; PROTEIN CONFORMATION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION; ANIMAL; DRUG EFFECT; HEK293 CELL LINE; HETEROLOGOUS IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOLOGY; PRECLINICAL STUDY; PRIMATE LENTIVIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNIZATION; LENTIVIRUSES, PRIMATE; MACACA MULATTA;

EID: 85048746314     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-04758-9     Document Type: Article

References (62)

1. Wyatt, R. &Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 (1998).
2. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. &Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113 (2008).
3. Sattentau, Q. J. &Moore, J. P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174, 407-415 (1991).
4. Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
5. Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000).
6. Mascola, J. R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
7. Shibata, R. et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5, 204-210 (1999).
8. Veillette, M. et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 88, 2633-2644 (2014).
9. Williams, K. L. et al. HIV-specific CD4-induced antibodies mediate broad and potent antibody-dependent cellular cytotoxicity activity and are commonly detected in plasma from HIV-infected humans. EBioMedicine 2, 1464-1477 (2015).
10. Guan, Y. et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl Acad. Sci. USA 110, E69-E78 (2013).
11. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
12. Horwitz, J. A. et al. Non-neutralizing antibodies alter the course of HIV-1 infection in vivo. Cell 170, 637-648 (2017).
13. Haynes, B. F. et al. HIV-host interactions: implications for vaccine design. Cell Host Microbe 19, 292-303 (2016).
14. Haynes, B. F. &Burton, D. R. Developing an HIV vaccine. Science 355, 1129-1130 (2017).
15. Labrijn, A. F. et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77, 10557-10565 (2003).
16. Chen, B. K., Gandhi, R. T. &Baltimore, D. CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of Vpu, Env, and Nef. J. Virol. 70, 6044-6053 (1996).
17. Arias, J. F. et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc. Natl Acad. Sci. USA 111, 6425-6430 (2014).
18. von Bredow, B. et al. Envelope glycoprotein internalization protects human and simian immunodeficiency virus-infected cells from antibody-dependent cell-mediated cytotoxicity. J. Virol. 89, 10648-10655 (2015).
19. Alvarez, R. A. et al. HIV-1 Vpu antagonism of tetherin inhibits antibodydependent cellular cytotoxic responses by natural killer cells. J. Virol. 88, 6031-6046 (2014).
20. Richard, J. et al. BST-2 expression modulates small CD4-mimetic sensitization of HIV-1-infected cells to antibody-dependent cellular cytotoxicity. J. Virol. 91, e00219-17 (2017).
21. Fouts, T. R., Binley, J. M., Trkola, A., Robinson, J. E. &Moore, J. P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71, 2779-2785 (1997).
22. Munro, J. B. et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346, 759-763 (2014).
23. Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
24. Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
25. Decker, J. M. et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201, 1407-1419 (2005).
26. Davis, K. L. et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387, 414-426 (2009).
27. Forsell, M. N. et al. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog. 4, e1000171 (2008).
28. Zhao, Q. et al. Identification of N-phenyl-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339, 213-225 (2005).
29. Madani, N. et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16, 1689-1701 (2008).
30. Kwon, Y. D. et al. Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site. PLoS ONE 9, e85940 (2014).
31. Melillo, B. et al. Small-molecule CD4-mimics: structure-based optimization of HIV-1 entry inhibition. ACS Med. Chem. Lett. 7, 330-334 (2016).
32. Curreli, F. et al. Synthesis, antiviral potency, in vitro ADMET, and X-ray structure of potent CD4 mimics as entry inhibitors that target the Phe43 cavity of HIV-1 gp120. J. Med. Chem. 60, 3124-3153 (2017).
33. Schön, A. et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45, 10973-10980 (2006).
34. Yoshimura, K. et al. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 84, 7558-7568 (2010).
35. Madani, N. et al. CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies. J. Virol. 88, 6542-6555 (2014).
36. Madani, N. et al. Antibodies elicited by multiple envelope glycoprotein immunogens in primates neutralize primary human immunodeficiency viruses (HIV-1) sensitized by CD4-mimetic compounds. J. Virol. 90, 5031-5046 (2016).
37. Richard, J. et al. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc. Natl Acad. Sci. USA 112, E2687-E2694 (2015).
38. Richard, J. et al. Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anti-cluster A ADCC epitopes on HIV-1 envelope glycoproteins. EBioMedicine 12, 208-218 (2016).
39. Asmal, M. et al. Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 475, 37-45 (2015).
40. Foley, B. et al. HIV Sequence Compendium. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, LA-UR 13-26007. http://www.hiv.lanl.gov/ (2013).
41. Kaplan, E. L. &Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481 (1958).
42. Spouge, J. L. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc. Natl Acad. Sci. USA 89, 7581-7585 (1992).
43. Morrison, L. A., Lukacher, A. E., Braciale, L. L., Fan, D. P. &Braciale, T. J. Differences in antigen presentation to MHC class 1-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J. Exp. Med. 163, 903-921 (1986).
44. Takahashi, H. et al. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344, 873-875 (1990).
45. Madani, N. et al. Activation and inactivation of primary human immunodeficiency virus envelope glycoprotein trimers by CD4-mimetic compounds. J. Virol. 91, e01880-16 (2017).
46. Rizzuto, C. et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 1949-1953 (1998).
47. Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
48. Nashan, B. et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350, 1193-1198 (1997).
49. Kovarik, J. et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 64, 1701-1705 (1997).
50. Queen, C. et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 86, 10029-10033 (1989).
51. Junghans, R. P. et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50, 1495-1502 (1990).
52. Whittle, J. R. et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 108, 14216-14221 (2011).
53. Rho, H. M. et al. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 112, 355-360 (1981).
54. Tukey, J. Comparing individual means in the analysis of variance. Biometrics 5, 99-114 (1949).
55. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163-170 (1966).
56. Bewick, V., Cheek, L. &Ball, J. Statistics review 12: survival analysis. Crit. Care. 8, 389-394 (2004).
57. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
58. Robert, X. &Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320-W324 (2014).
59. Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206, 1273-1289 (2009).
60. Kimura, M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16, 111-120 (1980).
61. Saitou, N. &Nei, M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406-425 (1987).
62. Salazar-Gonzalez, J. F. et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J. Virol. 85, 2751-2763 (2011).